Delcath Systems, Inc. to Participate at Upcoming Investor Conferences

View printer-friendly version

NEW YORK, Feb. 25  -- Delcath Systems, Inc. (Nasdaq: DCTH) announced today that it will present at the following two investor conferences in March 2010:

The Cowen and Company 30th Annual Health Care Conference
Wednesday, March 10, 2010
Boston, MA
9:30 a.m. ET
Eamonn Hobbs, CEO of Delcath, and David McDonald, CFO of Delcath

ROTH Capital Partners 22nd Annual OC Growth Stock Conference
Tuesday, March 16, 2010
Dana Point, CA
1:00 p.m. PT/4:00 p.m. ET
David McDonald, CFO of Delcath

Management will review the company's business strategy and recent corporate developments. Delcath will offer live video webcasts of its presentations which may be accessed on the Investors section of the Company's website at www.delcath.com. An archived replay of the presentations will be available for 30 days, also at www.delcath.com.

About Delcath Systems, Inc.
Delcath Systems, Inc. is a medical technology company specializing in cancer treatment. The Company is testing a proprietary, patented drug delivery system for the treatment of primary and metastatic liver cancers. Delcath's novel drug delivery platform is testing the delivery of ultra-high doses of anti-cancer agents to the liver while controlling the systemic exposure of those agents.  In addition to its fully enrolled Phase III metastatic melanoma study, the Company is currently conducting trials to treat other forms of tumor metastases to the liver. The Company maintains a broad intellectual property portfolio on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at
www.delcath.com.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.

This Site contains information and press releases about us. This information should be considered accurate only as of the date prepared. You acknowledge that this information may change over time and you should not assume that the information is accurate at a later date. Delcath Systems, Inc. is not obligated to update the press releases and information contained in this section of the Site.